Tempest Therapeutics (NASDAQ:TPST) Given Overweight Rating at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a report issued on Friday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

A number of other equities analysts also recently weighed in on TPST. William Blair restated an outperform rating on shares of Tempest Therapeutics in a research note on Wednesday, March 20th. Scotiabank started coverage on Tempest Therapeutics in a research note on Thursday, March 14th. They issued a sector outperform rating and a $13.00 target price on the stock. Finally, HC Wainwright restated a buy rating and issued a $47.00 target price on shares of Tempest Therapeutics in a research note on Thursday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of Buy and an average target price of $20.75.

Tempest Therapeutics Price Performance

TPST stock opened at $2.03 on Friday. The company has a market capitalization of $45.10 million, a P/E ratio of -1.18 and a beta of -1.78. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.13 and a current ratio of 3.13. Tempest Therapeutics has a 52-week low of $0.17 and a 52-week high of $9.77. The business has a 50-day simple moving average of $3.24 and a two-hundred day simple moving average of $3.69.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.08. Research analysts expect that Tempest Therapeutics will post -1.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC increased its stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after purchasing an additional 11,689 shares during the quarter. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 at the end of the most recent quarter. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.